PTC THERAPEUTICS ($PTCT) posted quarterly earnings results for Q1 2026 on Thursday, May 7th. The company reported earnings of -$0.03 per share, beating estimates of -$0.48 by $0.45. The company also reported revenue of $272,550,000, beating estimates of $223,181,528 by $49,368,472.
Stock price change since market close: +8.54%
You can see Quiver Quantitative's $PTCT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PTC THERAPEUTICS Insider Trading Activity
PTC THERAPEUTICS insiders have traded $PTCT stock on the open market 129 times in the past 6 months. Of those trades, 0 have been purchases and 129 have been sales.
Here’s a breakdown of recent trading of $PTCT stock by insiders over the last 6 months:
- NEIL GREGORY ALMSTEAD (CHIEF TECHNICAL OPS OFFICER) has made 0 purchases and 36 sales selling 169,964 shares for an estimated $13,171,461.
- ERIC PAUWELS (CHIEF BUSINESS OFFICER) has made 0 purchases and 26 sales selling 77,508 shares for an estimated $5,881,385.
- MATTHEW B. KLEIN (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 8 sales selling 35,079 shares for an estimated $2,597,010.
- MARK ELLIOTT BOULDING (EXEC. VP AND CLO) has made 0 purchases and 29 sales selling 29,221 shares for an estimated $2,161,269.
- ALLAN STEVEN JACOBSON has made 0 purchases and 10 sales selling 26,000 shares for an estimated $2,132,018.
- STEPHANIE OKEY has made 0 purchases and 3 sales selling 21,500 shares for an estimated $1,463,075.
- EMMA REEVE has made 0 purchases and 4 sales selling 18,800 shares for an estimated $1,454,720.
- LEE SCOTT GOLDEN (EVP & CHIEF MEDICAL OFFICER) has made 0 purchases and 6 sales selling 16,161 shares for an estimated $1,081,514.
- GLENN JR MD PHD STEELE sold 12,000 shares for an estimated $916,199
- CHRISTINE MARIE UTTER (SVP, CHIEF ACCOUNTING OFFICER) has made 0 purchases and 4 sales selling 6,144 shares for an estimated $453,951.
- PIERRE GRAVIER (CHIEF FINANCIAL OFFICER) has made 0 purchases and 2 sales selling 5,131 shares for an estimated $372,121.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
PTC THERAPEUTICS Hedge Fund Activity
We have seen 203 institutional investors add shares of PTC THERAPEUTICS stock to their portfolio, and 147 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 5,648,258 shares (+79.2%) to their portfolio in Q4 2025, for an estimated $429,041,677
- JANUS HENDERSON GROUP PLC added 1,077,776 shares (+28.6%) to their portfolio in Q4 2025, for an estimated $81,867,864
- STATE STREET CORP added 1,071,343 shares (+34.2%) to their portfolio in Q4 2025, for an estimated $81,379,214
- WELLINGTON MANAGEMENT GROUP LLP removed 1,051,239 shares (-21.4%) from their portfolio in Q4 2025, for an estimated $79,852,114
- MILLENNIUM MANAGEMENT LLC removed 1,033,987 shares (-97.9%) from their portfolio in Q4 2025, for an estimated $78,541,652
- TORONTO DOMINION BANK added 891,690 shares (+27.5%) to their portfolio in Q4 2025, for an estimated $67,732,772
- BNP PARIBAS FINANCIAL MARKETS added 808,515 shares (+4013.1%) to their portfolio in Q4 2025, for an estimated $61,414,799
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
PTC THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $PTCT recently. We have seen 6 analysts offer price targets for $PTCT in the last 6 months, with a median target of $89.0.
Here are some recent targets:
- Faisal Khurshid from Jefferies set a target price of $76.0 on 03/30/2026
- Jeffrey Hung from Morgan Stanley set a target price of $92.0 on 02/23/2026
- Tazeen Ahmad from B of A Securities set a target price of $93.0 on 02/20/2026
- Brian Abrahams from RBC Capital set a target price of $82.0 on 02/20/2026
- Benjamin Burnett from Wells Fargo set a target price of $86.0 on 02/20/2026
- Eliana Merle from Barclays set a target price of $119.0 on 01/28/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
